Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy.

A C Wolff1

  • 1The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231-1000, USA. awolff@jhmi.edu

Current Opinion in Oncology
|November 21, 2000
PubMed
Summary
This summary is machine-generated.

This review covers advances in breast cancer systemic therapy, including hormonal prevention, tamoxifen benefits, and adjuvant strategies. It also discusses palliative options, antibody therapies, and taxane use in early and advanced stages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

HER2DX genomic test in early-stage HER2-positive breast cancer.

ESMO open·2024
Same author

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

ESMO open·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

Lifestyle medicine for cancer survivorship.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • The field of systemic therapy for breast cancer is rapidly evolving.
  • Key areas of advancement include hormonal prevention, noninvasive disease treatment, and adjuvant therapy optimization.
  • Emerging data also impact palliative care and novel therapeutic targets.

Purpose of the Study:

  • To provide a comprehensive review of recent findings in breast cancer systemic therapy.
  • To discuss updates on hormonal prevention, tamoxifen efficacy, and adjuvant chemoendocrine regimens.
  • To highlight new data on palliative options, bisphosphonates, antibody therapies, novel targets, and taxane utilization.

Main Methods:

  • Review of current scientific literature and recent clinical trial data.

Related Experiment Videos

  • Synthesis of information on hormonal prevention, primary systemic therapy, and adjuvant strategies.
  • Analysis of data concerning palliative care, bisphosphonates, antibody therapies, and taxanes.

    • Main Results:

    • Expanded knowledge on hormonal prevention for high-risk women and tamoxifen's role in noninvasive disease.
    • Updated insights into primary systemic therapy and optimization of adjuvant chemoendocrine regimens.
    • New data on palliative options, bisphosphonates, antibody therapies, novel targets, and evolving taxane schedules.

    Conclusions:

    • Systemic therapy for breast cancer encompasses a wide range of evolving strategies.
    • Continued research is crucial for optimizing treatment outcomes across all stages of breast cancer.
    • Recent findings offer improved options for prevention, treatment, and palliative care.